The Zhitong Finance App learned that Kingsley Biotech (01548) rose nearly 12% in early trading. As of press release, it rose 7.28% to HK$33.6, with a turnover of HK$559 million.

According to a research report published by Morgan Stanley, private equity financing for AI drug research and development (AIDD) companies in China reached 15.8 billion yuan in the first nine months of this year, an increase of 312% on an annualized basis, involving a total of 57 rounds of financing. Investors are still selective and prefer leading platforms with molecular design capabilities.

The bank believes that as AIDD improves its ability to generate candidate binding molecules, demand is expanding from gene synthesis and protein expression to binding assays, functional verification, and developability testing, creating opportunities for wet laboratory service providers such as Kingsley Biotech. The company expects AIDD revenue to more than double in 2027 compared to 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.